Amycretin

Novo Nordisk

Amycretin is an experimental peptide that activates two appetite-regulating pathways from a single molecule: the GLP-1 receptor and the amylin receptor. This co-agonist design is the strategic idea behind it — rather than combining two separate drugs, amycretin folds incretin (GLP-1) and amylin biology into one long-acting agent. Amylin, a hormone co-secreted with insulin, promotes satiety and slows gastric emptying through mechanisms that are complementary to, and partly independent of, GLP-1, which is why pairing the two is attractive for weight management. Novo Nordisk is advancing amycretin in two formats, which is unusual: a subcutaneous injectable and an oral version. In early-phase clinical work, both produced striking weight reductions for such short durations — reported figures include roughly 13% mean weight loss over about 12 weeks with the oral form in a Phase 1 study, and figures in the low-20% range over about 36 weeks with the subcutaneous form in Phase 1b/2a work. These are early, small studies, so the numbers should be read as promising signals rather than settled efficacy. Amycretin is not approved anywhere and remains investigational; larger Phase 2 and Phase 3 trials are required to confirm efficacy, characterize gastrointestinal tolerability during titration, and establish long-term safety. It is included here as a reference entry on an emerging metabolic drug, not as a product available for legitimate purchase or self-administration.